SGMS1 and chronic inflammatory demyelinating polyradiculoneuropathy: If in CIDP the level of miR-31-5p decreases (as we observe in our studies, CIDP patients not treated with IgIV have very low levels of this miR compared to control and treated patients), this may directly affect the increase in the level of its target, SGMS1, and consequently sphingomyelin.